Figure 2. Preclinical subcutaneous mouse models using RM9-Luc-pIRES-KLK3 cells (n = 7).

A. Bioluminescence images in a representative subcutaneous mouse model. Animals were imaged weekly for 3 weeks from the third day after injection. B. Tumor progression was monitored by serum PSA (ng/ml) (i), tumor volume (mm³) (ii) and bioluminescent imaging (photos/s) (iii) on days 3, 7, 14, and 21 after RM9-Luc-pIRES-KLK3 injection. Mean values were analyzed among groups. * p < 0.05 C. Comparison between bioluminescence intensity and the current methods of monitoring tumor size and serum PSA levels. The observed bioluminescent imaging (photos/s) was proportional to the serum PSA (ng/ml) (R² coefficient: 0.896) (i) and tumor volume (mm³) (R² coefficient: 0.899) (ii), R² coefficient: 0.799 was proportional between serum PSA (ng/ml) and tumor volume (mm³) (iii).